I read with interest the article by Wang et al1 titled “High-Dose vs Non–High-Dose Proton Pump Inhibitors After Endoscopic Treatment in Patients With Bleeding Peptic Ulcer.” The authors analyzed 1157 patients from 7 randomized studies and found that non–high-dose and high-dose PPI groups had similar rebleeding episodes, surgical intervention, and mortality rates after endoscopic therapy.
However, these results are different from the international consensus and previous observation of mine and my colleagues. Several points require further clarification. First, endoscopic hemostatic therapy is not indicated for patients with low-risk stigmata (eg, a clean-based ulcer or a nonprotuberant pigmented dot in an ulcer base) who have a low rebleeding rate.2,3 Unfortunately, Wang et al1 have cited some studies that included low-risk patients: Yilmaz et al4 included 190 patients with low-risk stigmata (clean base, n = 144; flat pigmented spots, n = 46), while Bajaj et al5 included 11 patients (44%) with low-risk stigmata. In these low-risk patients, rebleeding rates may be similar with either high or low doses of PPIs. Therefore, the conclusion of Wang et al1 may be misleading.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.